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Background: The aim of the study was to determine the costs of treating schizophrenia from the perspective of
the statutory health insurance, as well as the identification of predictors of hospitalisation of formerly stable
schizophrenia patients.
Methods: Claims data for the years 2004–2006 were analysed. Patients who did not have to be treated in a hospital
as a result of an ICD diagnosis F20 both in the year 2005 as well as also in 2006 were defined as stable patients. In
contrast, those patients who had to be treated in a hospital in 2006 because of a diagnosis of schizophrenia were
defined as unstable. In addition to the overall healthcare costs, the costs specific to schizophrenia were also
analysed. Also, based on binary logistic regression analysis, predictors for hospital treatment were determined.
Results: 8497 stable and 1449 unstable patients were identified. The schizophrenia specific costs for stable patients
were € 1605 and the overall costs were € 4029 in 2006, respectively. Unstable patients had indication-specific costs
amounting to € 12864 and overall health care costs of € 16824. For unstable patients, the costs of hospital treatment
were identified as being a substantial cost area. Predictors for a higher probability of hospital treatment were: female
patients, at least one rehabilitation measure, at least one stay in hospital in 2004, and being co-morbid with substance
abuse. In contrast, older patients, who were treated with concomitant medications, and if they received a continuous
drug therapy in all quarters of a year had a lower probability of hospitalisation. In addition, an increased number of
visits to a doctor reduced the probability of hospitalisation. The variable ‘depot medication’ were close to significance
and the variable ‘inability to work lasting more than six weeks’ had, in contrast, no significant influence.
Conclusions: The schizophrenia specific and overall health care costs of unstable patients were clearly higher than was
the case with stable patients and mainly determined by inpatient hospital treatment. A range of potential predicting
factors which can be extracted from routine claims data have a positive or negative influence on the probability of
treatment in hospital.
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Schizophrenia is a serious illness with considerable eco-
nomic importance [1]. Because of the specific characteris-
tics of the illness, schizophrenia is considered to be one of
the most costly mental disorders [2]. According to official
cost data compiled by the Federal Office of Statistics
schizophrenia (ICD F20) resulted in direct costs of around
2.0 billion Euro to the statutory health insurance in 2008
[3]. In addition to this, there are much higher indirect
costs which, at present, are not recorded or evaluated in
any routine statistics [4-7]. The official statistics for 2008
indicate, however, that as a result of this disease in total
86,000 years of employment were lost [3]. The causes of
these higher costs lie in the young age, at which patients
first become ill (between the ages of 18 and 35), as well as
the tendency for the illness to become chronic [8].
Despite the increasing economic importance of schizo-
phrenia, systematic cost analyses based on the use of
health economic methods have, up until now, only been
carried out sporadically in Germany [7,9,10]. In view of
scarce resources in the healthcare system, however,
detailed cost analyses are becoming of increasing prac-
tical relevance. Gaining precise knowledge of individual
cost elements is likewise important, just as is information
about the individual and structural causes of variance in
claims for benefits [11].
Studies have identified, in particular, hospital stays as
being the cost driver [2,5,7,11-14]. Frequent inpatient
stays can endanger social and occupational integration,
as a result of the associated loss of the ability to work
and social participation and limit the individual´s quality
of life. Effective healthcare management can contribute
to identifying an increased risk of hospitalisation [15-17].
In this way, the medical care of patients could be
supported and more efficiently designed using innovative
outpatient treatment options such as psycho-education,
specialist nursing care, sociotherapy, treatment provided
by visiting the patient at home and care provided by
caregivers. In order to ensure this, the identification of
those factors influencing an increased risk of hospitalisa-
tion would be helpful.
Therefore, in the study presented here, not only the costs
of treating schizophrenia using a bottom-up approach from
the health insurance perspective was undertaken, but also
predictors for inpatient hospital treatment of formerly
stable patients were identified.
Methods
Data basis and study population
Routine data from a large statutory health insurance
scheme (which had approx. 6 million insured persons in
2006) for the years 2004–2006 were made available for
the study in an anonymous form. The study population
included all insured persons who in 2006 had at leastone schizophrenia-relevant diagnosis (ICD-10 code F20)
in a hospital or at least one verified schizophrenia-
relevant diagnosis in two different quarters of the year
coded in ambulatory treatment by a specialist.
The basis for the cost and predictor analysis presented
here was stable schizophrenic patients, i.e. those persons
with schizophrenia who, over a period of two years, did
not have to undergo inpatient treatment. Patients were
defined as being stable if they did not have to be treated
in a hospital in both 2005 as well as in 2006 with an ICD
diagnosis F20. In a second step stable patients were
compared with unstable patients. Patients were defined
as unstable if they were hospitalised because of a diagno-
sis of schizophrenia in 2006.
However, only those stable and unstable patients were
considered in the study who were at least 18 years of
age. In addition, only those individuals were considered
who were continuously insured with the health insurance
throughout the period 2004–2006.
The following data was available on a patient by patient
level: socio-demographic data (e.g. age and gender), data
on outpatient diagnosis and provided services, hospital
stays and treatments, rehabilitation measures, drug
prescriptions, remedies, and data relating to sick leave
payments. Health services which could not be included
explicitly in one of the specific cost domains were
summarised in the category ‘other services’. In addition to
the resources used that related directly to schizophrenia, it
was also possible to depict co-morbidity data as well as
costs associated with that.
Cost calculation and identification of indication-specific
resource use
The cost calculation was undertaken from the health
insurance perspective. Consequently, indirect costs and
costs that arose within other sectors of social insurance
were not taken into account. Co-payments and out-of-
pocket payments are also not relevant from the perspec-
tive of the health insurance as they do not have an
impact on their budget [18].
To identify schizophrenia specific drugs, the official
German ATC-classification was used. Antipsychotics
listed under N05A were defined as relevant substances
for the treatment of schizophrenia. For hospital treat-
ments, rehabilitation measures and data related to the
inability to work as well as sick leave payments, all
procedures that refer back to the ICD diagnosis F20 were
classified as being relevant to schizophrenia.
In the area of outpatient medical care the diagnosis and
accounting data were only available in separate databanks.
Diagnoses in German claims data are generally documen-
ted only on a quarterly basis whereas, in contrast, the ser-
vices provided are documented precisely on a day-by-day
basis. Therefore, in a first step, for each insured person
Zeidler et al. Health Economics Review 2012, 2:9 Page 3 of 8
http://www.healtheconomicsreview.com/content/2/1/9those accounting codes (EBM codes) were identified for
which, at the same quarter, a schizophrenia-relevant ICD
diagnosis F20 was documented. Those accounting codes
associated with a diagnosis of schizophrenia in the respect-
ive quarter were then adjusted on the basis of the valid
German uniform valuation standard (Gebührenordnung
Einheitlicher Bewertungsmaßstab: EBM).[19] Specific
accounting codes which could be invoiced by psychiatrists,
other specialists in nervous disorders and neurologists
were defined as indication-specific. This procedure has the
consequence that costs of outpatient treatment of schizo-
phrenia that incurred through general practitioner care
could not be recorded in relation to the indication-specific
resource use. However, these are reported with the cross-
indication total costs.
For costing the resource uses official German tariffs
were applied in the respective format which was used in
the given year. Were prices were available the actual
amount paid by the health insurance was included in the
analyses. For ambulatory services a point value for ser-
vices provided according to the Uniform Valuation
Scheme (EBM) of 0.035 € was applied [20,21].
Moreover, the use of resources for treatment in
the outpatients department of psychiatric institutes was
analysed. Treatment in the outpatients department of a
psychiatric institute were, in this context, defined as indi-
cation-specific and attributed to the costs for outpatient
services.
Study design predictor analysis
In addition to the cost analysis, based on a binary logistic
regression model, predictors for probability of inpatient
hospital treatment were identified. As predictors for
hospital stays, the variables age and gender of the
insured person, the type of drug therapy, the use of
depot medication, the continuity of drug treatment, the
number of visits to a doctor, the use of rehabilitation
measures, inability to work for more than six weeks, a
stay in hospital as a result of an ICD diagnose F20 in the
year 2004 and the presence of a comorbidity “Mental
and behavioural disorders as a result of psychotropic
substances” (ICD diagnosis F10-F19) were included.
Information regarding the gender of the insured
persons could be obtained directly from the data set.
Age was taken as an additional variable from the refer-
ence data. For the analysis of the influence of the type of
drug therapy, the subjects were allocated to one of seven
subgroups, depending on the type of medication, using
an algorithm proposed by Stargardt et al. [22]. Allocation
to the various drug groups was based on the ATC code.
Accordingly, patients who had received at least a
prescription of the active substance ziprasidone, cloza-
pine, olanzapine, quetiapine, amisulpride, risperidone,
zotepine or aripiprazole were allocated to the group ofatypical antipsychotics. Within this group of atypical
antipsychotics, persons who only received one atypical
substance were defined as non-switchers and individuals
who had had different atypical substances, either over-
lapping or one after the other, were defined as switchers.
For first generation antipsychotics, a differentiation into
high potency and low potency active ingredients was
made. Amongst the high potency antipsychotics, the
active ingredients fluphenazine, perphenazine, haloperidol,
bromperidol, benperidol, flupentixol, zuclopenthixol, flus-
pirilene and pimozide were included. The active
substances chlorpromazine, levomepromazine, promazine,
perazine, thoiridazine, melperone, pipamperone, chlor-
prothixene, sulpiride and prothipendyl were allocated to
the low potency antipsychotics group. Insured persons
who only received one antipsychotic were allocated to the
non-switchers while others receiving therapy with different
antipsychotics were allocated to the switchers.
Insured persons who received both atypical as well as
high potency typical antipsychotics were allocated to the
group “typical and atypical antipsychotics”. Individuals
who received atypical antipsychotics as well as low
potency typical antipsychotics were allocated to the
group “atypical antipsychotics with adjuvant therapy”.
Persons who received atypical antipsychotics as well as
high potency and low potency antipsychotics were allo-
cated to the group “typical and atypical antipsychotics”.
Finally, subjects who had not been prescribed antipsy-
chotics by the outpatient sector were subsumed in the
group “no relevant outpatient drug prescriptions”. The
various drug groups were coded as categorical variables.
At the same time, as a reference category, the drug
group “no relevant outpatient drug prescription” was
selected.
With reference to the influence of the drug therapy, an
additional analysis was carried out as to whether indivi-
duals received drug therapy with depot neuroleptics.
Treatment with depot neuroleptics was coded as a binary
variable with two categories based on whether a depot
prescription has been made or not. As both atypical and
typical antipsychotics are used in Germany in depot form
for the treatment of schizophrenia, this variable was
included in the analysis as an independent predictor.
The continuity of drug treatment as a predictor was
analysed by looking at the number of prescriptions in
a quarter. When an individual received at least one
antipsychotic prescription per quarter, he or she was
categorized as being continuously treated.
The number of outpatient treatment procedures was
deduced from the number of physician visits. As a further
predictor for hospitalisation, the influence of preceding
hospital stays was investigated. All those individuals were
identified who had already received hospital treatment in
the year 2004 with an F20 diagnosis. In addition, an
Table 1 Characteristics of stable and unstable patients
Stable
patients*
(n = 8497)
Unstable
patients**
(n = 1449)
Age (years), mean (SD) 49 (13.3) 42 (13.0)
Female, n (%) 4118 (48.8) 692 (47.8)
Patients with depot neuroleptics,
n (%)
1127 (13.3) 187 (12.9)
Continuously drug treated patients,
n (%)
4651 (54.7) 505 (34.9)
Mean number of doctor visits, (SD) 36 (27.7) 29 (31.5)
Number of patients with rehabilitation
paid by statutory health insurance,
n (%)
22 (0.3) 14 (1.0)
Number of patients with an inability to
work episode of more than six weeks,
n (%)
289 (3.4) 74 (5.1)
Number of patients with hospital
treatment in 2004, n (%)
822 (9.7) 271 (18.7)
Number of patients with co-morbid
substance abuse, n (%)
1167 (13.7) 269 (18.6)
* Stable patients were defined as those persons, who did not have to be
treated in a hospital in both 2005 as well as in 2006 due to a diagnosis of
schizophrenia (ICD F20).
** Patients were defined as unstable if they were hospitalised because of a
diagnosis of schizophrenia in 2006.
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a rehabilitation measure because of schizophrenia. Also,
all cases were investigated where there was inability to
work for more than six weeks because of schizophrenia.
Co-morbidities can also have an influence on the
course of the illness of schizophrenic patients. Conse-
quently, patients with co-morbid substance abuse have a
higher rate of re-hospitalisation, reduced psychosocial
functions, less patient concordance with treatment, as
well as a higher relapse rate than patients without such
substance consumption [23]. Therefore, all individuals
were identified in the data set who, in the outpatient or
inpatient sector, had at least one diagnosis of F10-F19.
The predictors were identified for the stable and
unstable patients over an observation period of twelve
months. The twelve month period used for stable
patients was the calendar year 2006. The period used for
identifying the predictors individually for unstable
patients was the twelve months before the first hospital
referral in 2006. A p-value of <0.05 was considered
significant.
Software
Microsoft Access was used for data storage. For data
analysis, both SPSS for Windows version 17, as well as
Microsoft Excel and Access (Versions 2007), were used.
Results
In total, n = 8497 stable (85.4%) and n= 1449 unstable
(14.6%) patients aged ≥18 years were identified. The
mean (SD) age of the stable patients was 49 (±13.3) years
and the percentage of female patients was 48.8%
(Table 1). The mean (SD) age of the unstable patient
subgroup was, 42 (±13,0) years old and the percentage of
female patients was 47.8%.
The schizophrenia specific costs of the stable patients
were € 1605 in 2006 (Table 2). Total costs of these
patients which also included the costs for co-morbidities
were € 4029. The schizophrenia specific costs of the
unstable patients (who were treated in a hospital in
2006) are with € 12864 higher on average. The total costs
of these individuals were likewise high amounting to
€ 16824. Schizophrenia specific costs of unstable patients
were eight times and overall health care costs were four
times higher than for the stable patients, respectively. The
percentage of hospital costs specific to schizophrenia was
84.1%.
The different drug groups which the stable patients
belonged to in 2006 are illustrated in Figure 1. A total of
n = 3870 patients (45.5%) were treated exclusively with
an atypical antipsychotic, n = 1323 insured persons
(15.6%) were treated with a typical antipsychotic drug
only, and n= 826 patients received no drug prescription
(9.7%).The drug groups of the unstable patients were deter-
mined for the twelve months before the first hospital
referral in 2006. A total of n = 437 patients (30.2%)
received only atypical antipsychotic drugs and did not
switch to any other active substances during the observa-
tion period, n = 124 patients (8.6%) were treated exclu-
sively with a typical antipsychotic drug and the
proportion of patients not treated with drugs was n = 417
persons (28.8%) which is higher than for stable patients.
If the results of the logistic regression model are
considered, it appears that, apart from the existence of a
depot medication, as well as an inability to work for
more than six weeks, all independent variables show a
significant influence (Table 3). Based on the sign of the
logistic regression coefficient (log odds ratio), it can be
determined whether the relationship between the
dependent variable hospitalisation and the independent
variables is positive or negative. These results revealed
that patients who were female, had at least one of the
rehabilitation measures, at least one hospital stay in 2004
or being co-morbid with substance abuse have a higher
probability of hospitalisation. For example, patients with
at least one hospital stay in 2004 have a twice as high
probability to be hospitalised than patients without a
hospital stay in 2004. Older patients, patients who were
treated with concomitant medication and patients who
received continuous drug therapy in all quarters of a year
had a lower probability of hospitalisation. Also, an
Table 2 Mean costs of stable and unstable patients in the year 2006 in €
Stable patients* (n=8497) Unstable patients** (n=1449)
Mean Standard deviation 95%-confidence-interval Mean Standard deviation 95%-confidence-interval
Schizophrenia specific costs
Medication 1124 1394 (1095,1154) 1292 1415 (1219,1365)
Outpatient
services 327 407 (318,336) 346 433 (323,368)
Remedies 20 194 (16,24) 16 149 (8,23)
Sick leave
payments 116 1561 (83,149) 331 2020 (227,435)
Hospitalisation 0 0 (0,0) 10816 10000 (10301,11332)
Rehabilitation 2 91 (0,4) 55 1178 (−5,116)
Other services 16 275 (10,22) 8 147 (1,16)
Total costs 1605 2266 (1557,1653) 12864 10614 (12317,13411)
Overall costs
Medications 1554 1940 (1513,1596) 1552 1756 (1462,1643)
Outpatient
services 726 710 (711,741) 769 1145 (710,828)
Remedies 80 403 (72,89) 48 233 (36,60)
Sick leave
payments 275 2347 (225,325) 751 3242 (584,918)
Hospitalisations 1233 4567 (1136,1330) 13423 11489 (12831,14016)
Rehabilitation 38 624 (24,51) 120 1446 (45,194)
Other services 123 841 (105,141) 161 977 (111,212)
Total costs 4029 6199 (3898,4161) 16824 12653 (16172,17476)
* Stable patients were defined as those persons, who did not have to be treated in a hospital in both 2005 as well as in 2006 due to a diagnosis of schizophrenia
(ICD F20).
** Patients were defined as unstable if they were hospitalised because of a diagnosis of schizophrenia in 2006.
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probability of hospitalisation.
The logistic regression model produced a nagelkerke
R2 of 16.6%. Nagelkerke R2 is an pseudo R2 which sum-
marizes how much of the variability of the depended55
(3.8%
146
(10.1%
417
(28.8%
3870 
(45.5%)
581 
(6.8%)
846
(10.0%)
1323
(15.6%)
425
(5.0%)
626
(7.4%)
826
(9.7%)
UnstabStable patients (n=8497)
Figure 1 Number of stable and unstable patients in different drug grovariable is successfully explained by the independent
variables. As an alternative to the regression model
presented above, we also calculated gradual models. For
this procedure, the independent variables are not incor-
porated in the model all at once, but gradually one by437
(30.2%)
140
(9.7%)
130
(9.0%)124
(8.6%)
)
)
)
Atypical antipsychotics 
(non-switcher)
Atypical antipsychotics 
(switcher)
Atypical antipsychotics with 
adjuvant therapy
Typical antipsychotics 
(non-Switcher)
Typical antipsychotics 
(switcher)
Typical and atypical 
antipsychotics
No relevant outpatient drug 
prescriptions
le patients (n=1449)
ups.
Table 3 Results of the logistic regression model for predictors of hospitalisation
Variable Regression Coefficient
(Log Odds Ratio)
Standard Error Odds Ratio 95%-Odds Ratio
Confidence-Interval
p-value
Age −0.038 0.003 0.962 (0.958,0.967) <0.001
Gender
Male
Female 0.179 0.062 1.196 1.058-1.351 0.004
Drug groups
No relevant outpatient drug
prescriptions
Atypical antipsychotics (non-switcher) −1.362 0.088 0.256 (0.216,0.305) <0.001
Atypical antipsychotics (switcher) −0.645 0.126 0.524 0.409-0.672 <0.001
Atypical antipsychotics with adjuvant therapy −0.839 0.126 0.432 0.337-0.553 <0.001
Typical antipsychotics (non-Switcher) −1.366 0.125 0.255 0.200-0.326 <0.001
Typical antipsychotics (switcher) −0.762 0.175 0.467 0.331-0.657 <0.001
Typical and atypical antipsychotics −0.376 0.136 0.686 0.526-0.896 0.006
Depot neuroleptics 0.198 0.105 1.219 0.993-1.497 0.058
Continuously drug treatment −0.657 0.073 0.519 0.450-0.598 <0.001
Number of doctor visits −0.008 0.001 0.992 0.990-0.995 <0.001
Rehabilitation 0.734 0.372 2.084 1.006-4.318 0.048
Inability to work episode of more than
six weeks
0.200 0.146 1.221 0.917-1.627 0.172
Hospital treatment in 2004 0.739 0.084 2.093 1.777-2.466 <0.001
Co-morbid substance abuse (ICD F10-F19) 0.278 0.081 1.320 1.125-1.548 0.001
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approach were the same as with the regression model.Discussion
On the basis of the results presented in this study, it is
possible to make precise statements about the distribution
of costs for stable and unstable patients over the various
cost domains paid by health insurances. The most signifi-
cant cost driver was costs for inpatient hospital treatment.
With € 10816, these constitute 84.1% of the indication-
specific treatment costs of unstable patients.
The results of the logistic regression model have con-
firmed that there is a significant influence for almost all
of the selected predictors on probability of hospitalisa-
tion. Only the independent variable ‘depot medication’
was close to significance and ‘inability to work for more
than six weeks’ had no significant influence. Patients
who were female, had at least one of the rehabilitation
measures, at least one hospital stay in 2004 or being
co-morbid with substance abuse have a higher probability
of hospitalisation than patients in whom these characteris-
tics are not present. In contrast, older patients, who were
treated with concomitant medication, and if they received
continuous drug therapy in all quarters of a year had a
lower probability of hospitalisation. In addition, anincreased number of physician visits reduces the probabil-
ity of hospitalisation.
Other analyses have been done in the past which have
investigated the relationship between different influencing
factors and inpatient treatment procedures in patients
suffering from schizophrenia. However, many studies
analyse predictors for rehospitalisation, i. e. the renewed
hospital referral of patients who, during the observation
period, have already received inpatient treatment at least
once [24-29]. Other studies have, at the same time, consid-
ered a number of psychological disorders without separ-
ately reporting the results of the regression model for
schizophrenia patients [30-33]. The diagnosis of schizo-
phrenia was used in these studies as an independent
predictor. One study which was concerned with the predic-
tion of relapses and also took into consideration stable
patients, used a more comprehensive definition of relapses
which, in addition to referrals to an inpatients department
of a hospital, also included attempted suicides [34]. More-
over, none of the studies referred to relate to the German
care provision context. However, the studies do suggest
important factors affecting inpatient treatment procedures.
The present study analysed these factors for the first time
for the German health care system.
The advantages of this study are that it addresses a
large country-wide study population, as well as routine
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that Statutory Health Insurance [GKV] routine data has
a substantial advantage for health economic cost analyses
from the perspective of a health insurance. In addition,
in the predictor analysis, a range of variables could be
identified that showed a significant influence on the
hospitalisation of previously stable patients. Identified
predictors are routinely recorded by the health insurance
companies and are, in principle, available for use at
any time.
In addition to the advantages referred to, the study
does, however, also show limitations. The reference data
contains not more detailed socioeconomic information,
for example regarding income classes or the social status
of the individuals. Also, clinical data, such as the severity
of the illness, are not available to health insurance com-
panies in Germany in their routine data as regulated by
social law. As a result, the two patient groups – the
stable and the unstable patients – can only be compared
to a limited extent, as differences with regard to the
severity of the psychological illness cannot be ruled out.
In addition, drugs prescribed in a hospital are included
directly in payments made direct to hospitals and are not
listed separately in the accounting data of the health
insurance. However, inclusion of these costs would only
widen the difference in medication costs for these two
groups making the unstable group even more costly.
Determination of the total direct costs of psychological
disorders is made more difficult by the strong fragmenta-
tion of the German care system [35]. Thus, for example,
not all medical rehabilitation measures which are made
use of because of a diagnosis of schizophrenia are
financed by the health insurance companies [36]. This is
linked to the division of responsibilities between those
who bear the costs of rehabilitation. In Germany, the
health insurance companies are traditionally responsible
for the rehabilitation of those who are not employed. For
the rehabilitation of those in employment or those who
are basically capable of working, as a rule, the Statutory
Pension Insurance is responsible. The aim of the study
presented here was, however, precisely the determination
of the use of resources that are relevant from the
perspective of a health insurance.
A challenge was presented by the fact that the ICD diag-
noses from outpatient care are reported quarterly, whereas
the cleared EBM codes, in contrast, are reported on a daily
basis. A direct allocation of individual clearing figures to
the diagnoses justifying the treatment was therefore not
possible. However, with the procedure which we used, it
was possible to identify the indication-specific treatment
costs generated by psychiatrists, specialists in nervous
disorders and neurologists. Treatment provided by general
practitioners had, in contrast, to be listed under the overall
health care costs.As the treatment of patients with schizophrenia is
partly carried out by general practitioners in Germany,
the total costs incurred for the treatment of this illness
should be located between the indication-specific and
overall costs. Even indication-specific allocation of
healthcare services, such as occupational therapy and
stress testing or providing support to the patient by
home help was not possible in every case. In such cases
the resource use had therefore to be included only in the
overall health care costs. Accordingly, the schizophrenia
specific costs quite definitely reflect the use of resources
attributable directly to the treatment of schizophrenia.
Moreover, the overall costs also include the use of
resources attributable indirectly to the treatment of
schizophrenia which cannot be clearly allocated to schizo-
phrenia as well as the costs for treating comorbidities.
The results of the study presented here do, however,
provide important information about the disease-specific
and overall costs of treatment of stable and non-stable
schizophrenia patients from the perspective of the statu-
tory health insurance. Furthermore, this is the first study
that identifies predictors for the hospitalisation of previ-
ously stable patients for the German healthcare context
based on routine data. In future studies it should be
explored how the predictors established in the present
analysis can be used in clinical practice to identify
patients with an increased risk of hospitalisation.
Conclusions
This claims data study demonstrates that schizophrenia-
specific and overall health care costs of unstable patients
are clearly higher than is the case with stable patients
and mainly determined by inpatient hospital treatment.
A range of potential predicting factors which can be
extracted from routine claims data have a positive or
negative influence on the probability of treatment in
hospital. The predictors established in the present analysis
should be used in clinical practice to identify patients with
an increased risk of hospitalisation.
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